Soaring initial public offerings for many biomedical startups are injecting cash into these companies as they seek cures for Covid-19, cancer and other diseases.
But as the frenzy builds, questions are arising about whether startups are wringing maximum value from these offerings.
Lured by scientific innovation and biotech’s role in developing…
